Plexus(NASDAQ) PLXS

Plexus Corp. NASDAQ:PLXS builds complex electronics for airplanes and medical machines. It makes high-tech parts that keep critical equipment running safely. The company also fixes products to make them last longer.

What Does Plexus Build?

• Industrial: Includes automation systems and tools used to make computer chips; generated $589.5 million in net sales during the quarter ended July 4, 2026.
• Healthcare and Life Sciences: Focuses on medical devices that improve patient care; generated $482.4 million in net sales during the quarter ended July 4, 2026.
• Aerospace and Defense: Provides mission-critical parts for aircraft and defense systems; generated $232.9 million in net sales during the quarter ended July 4, 2026.
• Aftermarket Services: Supports products throughout their entire lifecycle through repair and maintenance capabilities.

Recent Strategic Moves

• Refinanced the revolving credit facility in June 2026 to extend its maturity date to June 5, 2031.
• Launched a share repurchase program in May 2025 with authorization to buy back up to $100.0 million of common stock.
• Accelerated production ramps for new semiconductor capital equipment programs during the nine-month period ended July 4, 2026.
• Increased capital expenditures to $74.3 million during the nine months ended July 4, 2026, to support new customer programs.

A Focus on Precision

Plexus operates a global network of 27 facilities with over 20,000 team members across the Americas, Europe, and Asia. The company manages a high-mix business model that handles complex products requiring strict compliance with quality and regulatory standards.

Important Financial Figures

• Net sales reached $1,304.8 million for the three months ended July 4, 2026, up 28.1% year over year.
• Operating income was $177.6 million for the nine-month period ended July 4, 2026, up 19.0% year over year.
• The company repurchased 341,799 shares of its common stock for $63.6 million during the nine months ended July 4, 2026.
• Cash and cash equivalents were $314.6 million as of July 4, 2026, with 95% held by foreign subsidiaries.
• Annualized cash cycle decreased to 62 days for the three months ended July 4, 2026, down from 69 days in the prior year.

Bottom Line

Plexus has transitioned into a specialized manufacturing partner for industries that require extreme precision and strict regulatory compliance. Its focus on mission-critical sectors like healthcare and aerospace helps it maintain a vital role in the global technology supply chain.